Sponsored
Andrew Mitchell, Agilent Advanced Therapeutics, explains what it actually takes to produce biotherapeutics, from cell bank to commercial launch.
Andrew Mitchell, Agilent Advanced Therapeutics
Advertisement
Articles by Andrew Mitchell, Agilent Advanced Therapeutics
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
2
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
3
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
4
Teva Licenses US Rights to Samsung Bioepis TNF Inhibitor Biosimilars
5